Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer

Completed · Phase 1

Conditions studied: Pancreatic Cancer

In brief

The purpose of this study is to test the effectiveness and safety of the drug combination of gemcitabine and capecitabine (Xeloda) in patients with advanced pancreatic cancer.

Key facts

Study ID

NCT00316420

Run by

Swedish Medical Center

People needed

20

Starts

2003-12-01

Expected to finish

2009-08-01

Last updated by the study team

2010-03-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Metastatic or unresectable pancreatic cancer
• No prior chemotherapy except radiation-sensitizing doses of 5-FU
• No radiotherapy less than 4 weeks prior to the start of the study

You may not qualify if…

• Prior unanticipated severe reaction to fluoropyrimidine therapy or known hypersensitivity to 5-FU
• Moderate to severe renal impairment
• Uncontrolled diabetes
• Inability to swallow tablets

Where it is running

• Swedish Medical Center Cancer Institute — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.